A phase I/II study of DHP107, a novel oral paclitaxel formulation, in patients with advanced solid tumors (phase I) and gastric cancer (phase II).

医学 中性粒细胞减少症 发热性中性粒细胞减少症 紫杉醇 加药 内科学 化疗 癌症 耐火材料(行星科学) 临床研究阶段 胃肠病学 实体瘤疗效评价标准 毒性 肿瘤科 外科 物理 天体生物学
作者
Min‐Hee Ryu,Baek‐Yeol Ryoo,Tae Won Kim,Sung‐Bae Kim,Hyeong‐Seok Lim,Kyun‐Seop Bae,Sook Ryun Park,Yeong-Woo Jo,Hyun-Ju Cho,Yoon‐Koo Kang
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:32 (3_suppl): 101-101 被引量:3
标识
DOI:10.1200/jco.2014.32.3_suppl.101
摘要

101 Background: Paclitaxel has been proven to be effective and widely used in various types of cancers. DHP107 is a novel oral paclitaxel formulation. In the previous first-in-human study, DHP107 showed no DLTs at a single dose-escalating schedule and was reported safe and feasible in patients with advanced malignancies. This study was conducted to determine 1) recommended dose (RD) for multiple dosing of DHP107 in patients with metastatic solid tumor and 2) efficacy in patients with advanced gastric cancer (AGC). Methods: In phase I study, standard 3 + 3 dose escalation scheme was used, and the planned dose of DHP107 was 150 mg/m 2 bid at level 1, 200 mg/m 2 bid at level 2, and 250 mg/m 2 bid at level 3 on days 1, 8, and 15, every 4 weeks. In phase II study planned by Simon’s optimal two stage design (P 0 =0.05, P 1 =0.25, α=0.05, and β=0.2), DHP107 was administered at the RD in patients with AGC refractory to first-line chemotherapy containing fluoropyrimidine and platinum. Results: In the phase I study, no dose-limiting toxicity (DLT) was observed at level 1 (n=3) and at level 2 (n=6). At level 3, 2 out of 4 patients showed a DLT (one grade 4 neutropenia over 7 days and one febrile neutropenia). At additional dose level 2A (225 mg/m 2 bid), 2 out of 4 patients experienced febrile neutropenia. Finally, the RD of DHP107 was determined as level 2 (200 mg/m 2 bid). In PK analysis, 200 mg/m 2 bid of DHP107 showed similar AUC, C max and half-life to i.v. paclitaxel at 80 mg/m 2 . Out of the 11 patients enrolled in the phase II study, 3 patients achieved a confirmed partial response (27%; 95% C.I. 0-59%). Grade 3/4 adverse events with frequency > 5% included neutropenia (27.3%), stomatitis (18.2%), anemia (9.1%), and febrile neutropenia (9.1%). There was no treatment-related death. Conclusions: RD of DHP107 was determined as 200 mg/m 2 bid. At the RD, DHP107 was generally well tolerated and showed anti-tumor activity comparable to i.v. paclitaxel as a second-line chemotherapy in AGC. Based on these results, a phase III study to compare DHP107 with i.v. paclitaxel is currently ongoing in AGC. This study was supported by DAEHWA Pharmaceutical Co. and Gangwon Institute for Regional Program Evaluation by Korean government.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
丰富的宛亦完成签到 ,获得积分10
刚刚
清新的寄翠完成签到 ,获得积分10
2秒前
12完成签到,获得积分20
4秒前
不安毛豆发布了新的文献求助10
4秒前
情怀应助布丁采纳,获得10
6秒前
Wd发布了新的文献求助10
6秒前
任性翠安完成签到 ,获得积分10
8秒前
橘子汽水完成签到,获得积分10
9秒前
11秒前
13秒前
gnr2000应助搞怪网络采纳,获得20
13秒前
xinxin0215关注了科研通微信公众号
16秒前
风云鱼发布了新的文献求助10
16秒前
虚幻寄文发布了新的文献求助10
17秒前
整齐的大开应助灌饼采纳,获得10
22秒前
深情安青应助昵称采纳,获得10
23秒前
23秒前
25秒前
25秒前
30秒前
32秒前
布丁发布了新的文献求助10
33秒前
xinxin0215发布了新的文献求助10
37秒前
赘婿应助布丁采纳,获得10
37秒前
布丁发布了新的文献求助10
40秒前
xiayil完成签到 ,获得积分10
40秒前
40秒前
Seven完成签到,获得积分10
43秒前
ppg123应助小小林柒染采纳,获得30
44秒前
情怀应助忧心的书文采纳,获得10
44秒前
45秒前
Yola完成签到,获得积分10
47秒前
48秒前
49秒前
科研通AI2S应助魔幻小白菜采纳,获得10
53秒前
gnr2000应助搞怪网络采纳,获得20
54秒前
华仔应助fan采纳,获得10
54秒前
FashionBoy应助曹瑞霞采纳,获得30
55秒前
57秒前
1分钟前
高分求助中
Earth System Geophysics 1000
Co-opetition under Endogenous Bargaining Power 666
Studies on the inheritance of some characters in rice Oryza sativa L 600
Medicina di laboratorio. Logica e patologia clinica 600
Sarcolestes leedsi Lydekker, an ankylosaurian dinosaur from the Middle Jurassic of England 500
《关于整治突出dupin问题的实施意见》(厅字〔2019〕52号) 500
Language injustice and social equity in EMI policies in China 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3211782
求助须知:如何正确求助?哪些是违规求助? 2860609
关于积分的说明 8125098
捐赠科研通 2526487
什么是DOI,文献DOI怎么找? 1360316
科研通“疑难数据库(出版商)”最低求助积分说明 643182
邀请新用户注册赠送积分活动 615273